Podcasts about Regulatory compliance

Earn 1.0 CPD here: https://quiz.ensombl.com/ENSO-26022223-39570001 0.25 Technical Competence 0.25 Client Care and Practice 0.25 Regulatory Compliance & Consumer Protection 0.25 Professionalism and Ethics In this episode, Rocksy speaks with Jonathan Christie, Managing Director at Oreana Partnerships. They explore how Oreana Partnerships has evolved as a specialist, technology‑led, advice‑focused licensee and capital partner, which supports mature, predominantly pre‑retiree/retiree advice practices with governance, AI-enabled efficiency, succession and growth/acquisition strategies while maintaining a tightly curated, profitable national network. Jonathan Christie LinkedIn: https://www.linkedin.com/in/jonathan-christie-a8807561/ Oreana Partnerships Website: https://oreanapartnerships.com.au/ Explore the road less travelled at https://ensombl.com/go/20260224 General Disclaimer – https://www.ensombl.com/disclaimer/

Earn 1.0 CPD here: https://quiz.ensombl.com/ENSO-26021804-40420001 0.25 Technical Competence 0.25 Professionalism and Ethics 0.25 Regulatory Compliance and Consumer Protection 0.25 Client Care and Practice This week, Pat speaks with Aaron Breed, Product, Automation and Implementation Lead at rubica. They discuss how their shared “tell your story once” philosophy is driving the design of rubica's API‑first, AI‑ready CRM and operations platform - using custom forms, entity maps, and deep integrations (e.g. Teams, Microsoft, Salesforce) to unify client data, automate workflows, and deliver scalable, high‑quality advice experiences. Aaron Breed LinkedIn: https://www.linkedin.com/in/aaron-breed/ rubica Website: https://rubica.au/ Aaron's previous episode: https://ensombl.com/podcasts/advicetech110/ Between Meetings with Matt Heine – Discover a podcast for wealth professionals: https://ensombl.com/go/20260220 General Disclaimer – https://www.ensombl.com/disclaimer/

Earn 1.0 CPD here: https://quiz.ensombl.com/ENSO-26021522-54170001 0.25 Technical Competence 0.25 Client Care and Practice 0.25 Regulatory Compliance & Consumer Protection 0.25 Tax (Financial) Advice This week, Rocksy is joined by Rob Coyte, CEO of Shartru Wealth Management. They explore his career journey, the origins and philosophy of Shartru Wealth as a licensee, how their “Shartru Way” best‑of‑breed model, technology, and back‑office support help small advice firms run profitable, client‑centric businesses. Rob Coyte LinkedIn: https://www.linkedin.com/in/robcoyte/ Shartru Wealth Website: https://www.shartruwealth.com.au/ Explore the road less travelled at https://ensombl.com/go/20260217 General Disclaimer – https://www.ensombl.com/disclaimer/

Hosts Fran Chismar and Tom Knezick connect with Mike McGraw (Senior Project Manager. Regulatory Compliance and Wildlife Surveys; Senior Wildlife Biologist) of Princeton Hydro, and Santino Lauricella (Education Manager) of Bowman's Hill Wildflower Preserve, to discuss the Roots So Deep Documentary. Topics include how Mike became involved with the project, generational shifts in family owned agricultural businesses, and the live Q&A with Mike, Santino, and Fran from the Newtown Theater in PA on January, 21st, 2026. Music by Egocentric Plastic Men, Outro music by Dave Bennett. Rent the Roots So Deep Documentary Here. Follow Princeton Hydro Here. Follow Bowman's Hill Wildflower Preserve Here. Have a question or a comment?  Call (215) 346-6189. Follow Native Plants Healthy Planet – Website / Instagram / Facebook / YouTube Follow Fran Chismar Here. Buy a T-shirt, spread the message, and do some good. Visit our store Here! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Earn 1.0 CPD here: https://quiz.ensombl.com/ENSO-26021201-15270001 0.25 Technical Competence 0.25 Professionalism and Ethics 0.25 Regulatory Compliance and Consumer Protection 0.25 Client Care and Practice In this week's episode, Pat speaks with Clinton Cunningham, CEO at AdviseWell. They discuss how AI is rapidly evolving from simple file-note tools into agentic, end‑to‑end “intelligence layers” that orchestrate advice workflows across tech stacks, what large US/UK firms are doing, and how advisers can practically experiment with and adopt these tools in 2026. Clinton Cunningham LinkedIn: https://www.linkedin.com/in/clintoncunningham/ AdviseWell Website: https://www.advisewell.co/ Previous Episode: https://ensombl.com/podcasts/advicetech111/ Between Meetings with Matt Heine – Discover a podcast for wealth professionals: https://ensombl.com/go/20260213 General Disclaimer – https://www.ensombl.com/disclaimer/

Stories we're covering this week:• Michele Gooch Announces Candidacy for MISD School Board• Mansfield Teen Sentenced in Florida School Swatting Case• We'll Talk About Movin' Downtown Dirt in A Moment With the Mayor• Mansfield Mission Center Breaks Ground on New Facility• State Historical Marker Approved for Mansfield Community Leader• Public Input Welcome at Upcoming Desegregation Meeting• Goodwill to Open Larger Mansfield Store in April• Visit Mansfield Lists the Best Places to Locally Propose Marriage• In Sports, North Texas SC Signs MLS SuperDraft PickIn the Features Section:• Angel Biasatti talks about the role protein plays in your daily diet in Methodist Mansfield News to Know• We will talk with the city's Director of Regulatory Compliance on this week's 40 Under 40• Brian Certain serves up a drink that he describes as committed, deep and layered in this week's Cocktail of the WeekIn the talk segment, Steve talks with retired prosecuting attorney Denise Wilkerson. We are Mansfield's only source for news, talk and information. This is About Mansfield.

South Africa’s budget airline FlySafair is set to be acquired by local private equity firm Harith General Partners, a move that could reshape the domestic aviation landscape and help the airline comply with local ownership laws. Aviation expert Guy Leitch speaks to John Maytham about what the change in ownership could mean for FlySafair, its passengers, and the broader South African aviation industry, offering insight into whether this deal is a positive or concerning development for the sector. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Earn 0.75 CPD here: https://quiz.ensombl.com/ENSO-26021004-09270001 0.25 Technical Competence 0.25 Client Care and Practice 0.25 Regulatory Compliance and Consumer Protection Cathy is a Financial Adviser at Pollock Financial Planning. She and James discuss her career change from medical indemnity BDM to financial advice, her education journey and COVID-era licensing challenges, and her current role at Pollock Financial working within a shared-client, retiree-focused advice model that emphasises collaboration and current tech to support scalable, consistent client service. Cathy Kayess LinkedIn: https://www.linkedin.com/in/cathykayess/ Pollock Financial Planning Website: https://www.pollockfinancialplanning.com.au/ For a simpler, faster way to write risk visit https://ensombl.com/go/20260212 General Disclaimer – https://www.ensombl.com/disclaimer/

Earn 1.0 CPD here: https://quiz.ensombl.com/ENSO-26020823-36020001 0.25 Technical Competence 0.25 Client Care and Practice 0.25 Regulatory Compliance & Consumer Protection 0.25 Professionalism and Ethics In this episode, Rocksy is joined by Sam El Shammaa, CEO & Managing Director at Finchley & Kent. He discusses his personal and professional journey, the deliberate, values-led growth and service model of Finchley & Kent, and his optimistic outlook on the future of financial advice and adviser communities. Sam El Shammaa LinkedIn: https://www.linkedin.com/in/yselshammaa/ Finchley and Kent Website: https://www.finchleyandkent.com.au/ Marloo Website: https://www.gomarloo.com/au Explore the road less travelled at https://ensombl.com/go/20260210 General Disclaimer – https://www.ensombl.com/disclaimer/

Earn 0.75 CPD here: https://quiz.ensombl.com/ENSO-26020523-40390001 0.25 Client Care & Practice 0.25 Technical Competence 0.25 Regulatory Compliance and Consumer Protection In this first episode, Ben Donald is joined by Adam Crabbe, Risk Strategy Specialist at Zurich and Katherine Hayes, Director and Financial Advisor at Hayes & Co Insurance Services. They explore how financial planners can more confidently and profitably re‑engage with life insurance - especially risk and claims work - by using pre‑assessment tools, streamlined health questionnaires, and collaboration with risk specialists and insurers to better serve clients amid industry change. Adam Crabbe LinkedIn: https://www.linkedin.com/in/adamcrabbe/ Katherine Hayes LinkedIn: https://www.linkedin.com/in/katherine-hayes-44714830/ Hayes & Co Insurance Services Website: https://hcis.com.au/ Ben Donald LinkedIn: https://www.linkedin.com/in/ben-donald-a0363b78/ Visit The Adviser Portal and partner with Zurich and OnePath today: https://ensombl.com/go/20260209 General Disclaimer – https://www.ensombl.com/disclaimer/

Earn 0.75 CPD here: https://quiz.ensombl.com/ENSO-26020503-34590001 0.25 Technical Competence 0.25 Regulatory Compliance and Consumer Protection 0.25 Client Care and Practice In this episode, Pat speaks with Lachlan Brien, Consultant & Director at OnReport. They discuss how advice firms can turn fragmented data into actionable insights using Power BI, CRM as a source of truth, effective dashboard design, data quality and integrations, and the evolving role of AI in analytics. Lachlan Brien LinkedIn: https://www.linkedin.com/in/lachlan-brien-905b5a123/ OnReport Website: https://onreport.com.au/ Between Meetings with Matt Heine – Discover a podcast for wealth professionals: https://ensombl.com/go/20260206 General Disclaimer – https://www.ensombl.com/disclaimer/

Dr. Jeni Hayes, Senior Clinical Manager, Strategic Clinical Intelligence, and Dr. Heather Pace, Senior Clinical Manager, Ambulatory Care, join host Carolyn Liptak to discuss the Vizient Winter 2026 Spend Management Outlook, with a focus on pharmacy projections and key changes from prior outlooks. The episode also covers ambulatory care and self-administered drugs, biosimilar therapeutic insights, and dynamic pharmacy market forces.   Guest speaker:     Jeni Hayes, PharmD, BCPS   Senior Clinical Manager, Strategic Clinical Intelligence Vizient Spend Management Solutions   Heather Pace, PharmD   Senior Clinical Manager, Ambulatory Care Vizient Center for Pharmacy Practice Excellence     Host:   Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance & Revenue Integrity Center for Pharmacy Practice Excellence (CPPE) Vizient   00:05 — Introduction Announcer welcomes listeners to Verified Rx, produced by the Vizient Center for Pharmacy Practice Excellence.   00:14 — Episode Overview Host Carolyn Liptak, Pharmacy Executive Director at Vizient, introduces the Winter 2026 Spend Management Outlook (SMO). Focus areas: Pharmacy inflation projections Acute vs ambulatory care trends Provider-administered vs self-administered drugs Biosimilar therapeutic insights Dynamic pharmacy market forces shaping 2026–2030 Guests: Jeni Hayes, Senior Clinical Manager, Strategic Clinical Intelligence Heather Pace, Senior Clinical Manager, Ambulatory Care   01:09 — What Is the Spend Management Outlook (SMO)? Biannual Vizient publication projecting price trends across healthcare spend categories. Pharmacy headline: Inflation slightly lower than last edition Total spend still rising, driven by utilization growth and new technologies   01:49 — Top-Line Pharmacy Inflation Projection 2.84% projected drug inflation for purchases between July 2026 – June 2027. Down from 3.35% in the prior edition. Based on October 2024 – September 2025 wholesaler data. Heavily weighted toward highest-spend drugs. Contracted products show lower inflation; non-contract drugs still ~70% of spend.   02:45 — Inflation by Site of Care Acute Care 3.03% projected inflation Driven by: Sugammadex Kcentra Clotting factors Ambulatory Care 2.85% overall, but with key divergence: Provider-administered drugs: 3.35% Self-administered drugs: 2.43%   04:02 — Provider-Administered Drugs: What's Driving Growth Oncology infusions are the main drivers. Key agents: Keytruda Darzalex Faspro Continued growth due to: Expanded indications Increased outpatient infusion utilization Oncology split by site of care: Inpatient: High-cost CAR T (e.g., Yescarta) Outpatient: Infusions, bispecifics, emerging cellular therapies Emphasizes importance of site of care strategy.   05:14 — Self-Administered Drugs: Utilization Over Inflation Five key drivers: Autoimmune / inflammatory: Skyrizi, Dupixent, Rinvoq Diabetes / metabolic / weight loss: Ozempic, Wegovy, Mounjaro, Zepbound Spend growth fueled by: Media exposure Expanded indications Increased patient demand Opportunity for: Retail & specialty pharmacy optimization Margin capture Patient support (adherence, counseling, benefits investigation)   06:45 — New Section: Dynamic Pharmacy Market Forces (2026–2030) Seven strategic forces influencing pharmacy practice: Growth in specialty and cell & gene therapies Expansion of value- and outcomes-based contracting Siteofcare shifts toward ambulatory and home Digital transformation & automation Supply assurance and resilience Expanded pharmacist clinical scope & workforce models Regulatory and policy efforts to lower drug prices 340B changes IRA Medicare Part D negotiations   09:37 — Practical Takeaways for Pharmacy Leaders Use 2.84% inflation as a baseline — then customize using Vizient Pharmacy Analytics. Leverage segmented views to prioritize: Acute vs ambulatory strategies Provider-administered vs self-administered drugs Identify top spend movers and align them with long-term market forces. Consider: Specialty pharmacy expansion Site of care optimization   10:48 — Biosimilar Therapeutic Insights: 2025 Recap Heather Pace highlights: Shift from biosimilar approval to active adoption management. Ustekinumab (Stelara) as defining example: Multiple biosimilars Uptake driven by payer and PBM strategy Utilization varies widely based on: Formulary design Benefit alignment Biosimilars now actively steered, not passively adopted.   11:50 — Why Stelara Was a Turning Point PBM-developed, private-label biosimilars drove adoption. Net cost and copay design outweighed: Interchangeability status Manufacturer differentiation Sets expectations for future biologic launches.   12:25 — Operational Impact for Health Systems Expect payer-specific product preferences. Frequent switching will become routine. Key considerations: Siteofcare mandates Product presentation Supply chain logistics Billing & reimbursement complexity Clinical barriers are decreasing; workflow flexibility is critical.   13:09 — What to Expect From Biosimilars in 2026 Faster adoption timelines Earlier payer-driven switching Fewer preferred products Less reliance on reference product trial periods   13:45 — Biosimilars With Major 2026 Impact Eylea — multiple launches expected post-litigation Xolair — expansion into asthma/allergy and retail specialty Perjeta — oncology pathway disruption expected late 2026 / early 2027   15:01 — 2025 Biosimilars Impacting 2026 Ustekinumab (Stelara): broader formulary shifts Denosumab (Prolia, Xgeva): full year of impact; all interchangeable Eculizumab (Soliris): first rare-disease biosimilar entry   15:58 — FDA Biosimilar Guidance to Watch Late-2025 FDA guidance: Reduced reliance on clinical efficacy trials Greater emphasis on analytical similarity Aims to: Reduce development cost Accelerate market entry   16:26 — Interchangeability: Where Things Are Headed Moving toward expectation that all biosimilars are interchangeable. Shifts responsibility to: Payers Health systems Pharmacists managing transitions and education   17:17 — Biggest Shift in the Biosimilar Landscape Faster launches Larger scale adoption Payer strategy more influential than timing of approval Success depends on: Formulary fit Channel alignment Operational simplicity   17:41 — Final Biosimilar Insight Biosimilar strategies must be molecule-specific. One-size-fits-all approaches are no longer effective.   18:13 — Final Thoughts on the SMO Inflation projections are a starting point. Leaders should: Focus on top spend drugs Understand siteofcare and specialty drivers Translate projections into actionable budgets   18:40 — Resources Winter 2026 Spend Management Outlook available on Vizient's SMO Hub. Includes current and prior editions and related insights.   18:58 — Closing Carolyn thanks Jeni and Heather. Reminder to subscribe, like, and share feedback. Verified Rx is produced by the Vizient Center for Pharmacy Practice Excellence.   Links | Resources:  Vizient Spend Management Outlook webpage Vizient Winter 2026 Spend Management Outlook Vizient Biosimilars Therapeutic Insights   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed    

Stewart Alsop interviews Tomas Yu, CEO and founder of Turn-On Financial Technologies, on this episode of the Crazy Wisdom Podcast. They explore how Yu's company is revolutionizing the closed-loop payment ecosystem by creating a universal float system that allows gift card credits to be used across multiple merchants rather than being locked to a single business like Starbucks. The conversation covers the complexities of fintech regulation, the differences between open and closed loop payment systems, and Yu's unique background that combines Korean martial arts discipline with Mexican polo culture. They also dive into Yu's passion for polo, discussing the intimate relationship between rider and horse, the sport's elitist tendencies in different regions, and his efforts to build polo communities from El Paso to New Mexico. Find Tomas on LinkedIn under Tommy (TJ) Alvarez.Timestamps00:00 Introduction to TurnOn Technologies02:45 Understanding Float and Its Implications05:45 Decentralized Gift Card System08:39 Navigating the FinTech Landscape11:19 The Role of Merchants and Consumers14:15 Challenges in the Gift Card Market17:26 The Future of Payment Systems23:12 Understanding Payment Systems: Stripe and POS26:47 Regulatory Landscape: KYC and AML in Payments27:55 The Impact of Economic Conditions on Financial Systems36:39 Transitioning from Industrial to Information Age Finance38:18 Curiosity and Resourcefulness in the Information Age45:09 Social Media and the Dynamics of Attention46:26 From Restaurant to Polo: A Journey of Mentorship49:50 The Thrill of Polo: Learning and Obsession54:53 Building a Team: Breaking Elitism in Polo01:00:29 The Unique Bond: Understanding the Horse-Rider Relationship01:05:21 Polo Horses: Choosing the Right Breed for the GameKey Insights1. Turn-On Technologies is revolutionizing payment systems through behavioral finance by creating a decentralized "float" system. Unlike traditional gift cards that lock customers into single merchants like Starbucks, Turn-On allows universal credit that works across their entire merchant ecosystem. This addresses the massive gift card market where companies like Starbucks hold billions in customer funds that can only be used at their locations.2. The financial industry operates on an exclusionary "closed loop" versus "open loop" system that creates significant friction and fees. Closed loop systems keep money within specific ecosystems without conversion to cash, while open loop systems allow cash withdrawal but trigger heavy regulation. Every transaction through traditional payment processors like Stripe can cost merchants 3-8% in fees, representing a massive burden on businesses.3. Point-of-sale systems function as the financial bloodstream and credit scoring mechanism for businesses. These systems track all card transactions and serve as the primary data source for merchant lending decisions. The gap between POS records and bank deposits reveals cash transactions that businesses may not be reporting, making POS data crucial for assessing business creditworthiness and loan risk.4. Traditional FinTech professionals often miss obvious opportunities due to ego and institutional thinking. Yu encountered resistance from established FinTech experts who initially dismissed his gift card-focused approach, despite the trillion-dollar market size. The financial industry's complexity is sometimes artificially maintained to exclude outsiders rather than serve genuine regulatory purposes.5. The information age is creating a fundamental divide between curious, resourceful individuals and those stuck in credentialist systems. With AI and LLMs amplifying human capability, people who ask the right questions and maintain curiosity will become exponentially more effective. Meanwhile, those relying on traditional credentials without underlying curiosity will fall further behind, creating unprecedented economic and social divergence.6. Polo serves as a powerful business metaphor and relationship-building tool that mirrors modern entrepreneurial challenges. Like mixed martial arts evolved from testing individual disciplines, business success now requires being competent across multiple areas rather than excelling in just one specialty. The sport also creates unique networking opportunities and teaches valuable lessons about partnership between human and animal.7. International financial systems reveal how governments use complexity and capital controls to maintain power over citizens. Yu's observations about Argentina's financial restrictions and the prevalence of cash economies in Latin America illustrate how regulatory complexity often serves political rather than protective purposes, creating opportunities for alternative financial systems that provide genuine value to users.

Herzlich willkommen zu einer neuen Folge des Makler und Vermittler Podcasts! In dieser Episode spricht Torsten Jasper mit Lars Fuchs, dem Vorstandsvorsitzenden der Domcura. Es erwartet euch ein spannender Einblick in die Versicherungswelt – von den Anfängen im Bankensektor, über innovative Produktentwicklungen bis hin zu seiner Führungsrolle bei Domcura. Gemeinsam blicken die beiden auf über 30 Jahre Erfahrung im Finanz- und Versicherungssektor zurück. Im Zentrum des Gesprächs stehen aktuelle Themen wie der Einsatz künstlicher Intelligenz in der Schadenbearbeitung, innovative Ansätze im Assekuradeur-Modell und die Herausforderungen im Wohngebäudemarkt. Lars Fuchs teilt exklusive Einblicke in die digitale Transformation bei Domcura, berichtet über die Integration smarter Tools und Prozesse und erklärt, warum Menschlichkeit im Vertrieb trotz aller Technik weiterhin unerlässlich bleibt. Freut euch auf eine lebendige Diskussion rund um Veränderungen, neue Chancen und wie Domcura mit Mut und Innovationskraft die Zukunft des Versicherungsgeschäfts gestaltet. Viel Spaß beim Reinhören!

APS is seeking a rate increase of 14% this year. Anne Carlton, manager of regulatory compliance with APS joined the show to talk about why they are requesting this rate increase. 

SummaryIn this episode of The Compliance Guy, Sean Weiss interviews Joe Rivet, a healthcare attorney with extensive experience in federal matters, including prior authorization processes and the No Surprises Act. They discuss the potential changes in legislation regarding prior authorizations, the challenges faced by physicians in getting necessary treatments approved, and the implications of recent Supreme Court rulings on healthcare legislation. Joe shares insights on navigating appeals, the importance of advocating for patients, and the complexities of the IDR process.TakeawaysPrior authorization processes are being scrutinized for their impact on patient care.The proposed 'Doctors Know Best' bill aims to empower physicians.Advocating for patients is crucial, especially in off-label drug use cases.The No Surprises Act has significant implications for healthcare providers and patients.There is a lack of private right of action under the No Surprises Act.The IDR process is complicated and often exploited by private companies.Medical necessity determinations can be challenged, even after prior authorization approval.Physicians should not accept denials without exhausting all options.Recent Supreme Court rulings have clarified the limitations of private actions in healthcare disputes.Transparency in enforcement actions is needed for better accountability in healthcare.

Earn 0.75 CPD here: https://quiz.ensombl.com/ENSO-26012202-03130001 0.25 Regulatory Compliance and Consumer Protection 0.50 Client Care and Practice In this episode, Patrick speaks with Martin Morris and Sandeep Rao from Engagement Hub. They discuss how Engagement Hub has transformed into a comprehensive, AI-enhanced platform for advisers and clients, with a focus on improved engagement, compliance, and future plans for broader adoption and dealer group integration. Martin Morris LinkedIn: https://www.linkedin.com/in/martin-morris-182a902/ Sandeep Rao LinkedIn: https://www.linkedin.com/in/sandeep-rao-problemsolver/ Engagement Hub Website: https://www.engagementhub.net/ A world of business efficiency awaits you at Netwealth: https://ensombl.com/go/20260123 General Disclaimer – https://www.ensombl.com/disclaimer/

Prashant Mehrotra, Chief AI Officer at US Bank, discusses how the bank evaluates AI initiatives and scales projects from pilot to production. He explains how to build customer trust through responsible AI design and prepare for the future of autonomous banking in CXOTalk episode 906. This conversation covers key aspects of AI in business and AI implementation within a large banking institution.=======Please support our sponsor Emeritus: Explore executive education programs from Emeritus, in collaboration with top universities: https://cxotalk.partner.emeritus.org/=======Key topics discussed:→ Why AI should transform processes, not simply make them more efficient→ How U.S. Bank cut governance approval times in half by engaging risk partners early→ The critical role of baselines in determining whether AI pilots scale or fail→ Why "AI without data is a hallucination" and how the bank organizes Digital, Data, and AI under one leader→ Building AI literacy across the entire workforce, from executives to frontline associates→ The shift from building models to leveraging external foundation models at scale→ Balancing personalization with privacy in customer interactionsMehrotra emphasizes that the client remains the "North Star" for every AI initiative. He offers practical guidance on metrics, funding pilots through to production, and creating repeatable governance processes that accelerate rather than slow down AI deployment.

"The definition of insanity is repeating the same thing over and over and expecting a different result every time. That's a little bit how metadata management is often performed in companies."

In this episode of Disruption/Interruption, marketing veteran Ed Locher pulls back the curtain on B2B marketing's biggest lie: that the MQL machine actually drives growth. As CMO of PureFacts Financial Solutions and author of "Digital Transformation: People, Process and Technology," Ed reveals why 15 years of marketing automation created a sugar rush that's now crashing, and how AI can help fix it without repeating the same mistakes. This is a no-holds-barred conversation about emotional connection, the 95% of buyers marketers ignore, and why marketing tenure averages just 18 months. Four Key Takeaways: The MQL Mirage Is Built on a Lie 8:56Marketing automation promised accountability through MQLs, but overdelivering on MQL targets quarter after quarter never translated to actual revenue growth. The entire system targets only the 5% of the market ready to buy right now—ignoring the 95% who need demand creation, not demand capture. B2B Buying Committees Have Tripled in Size 16:30The buying committee for enterprise B2B purchases has exploded from 5 people to 16. You can't build credibility and trust with 16 stakeholders through email sequences—you need emotional connection and personalized storytelling that speaks to each person's specific drivers (CFO cares about ROI, compliance cares about regulations, operations cares about not making headlines). AI Raises the Floor, Not the Ceiling 29:59AI protects terrible marketers from themselves by raising the quality floor, but it hasn't raised the bar for great marketing. The real opportunity lies 3-4 standard deviations above the mean—where human empathy, emotional triggers, and genuine understanding of customer pain create outsized impact that AI can't replicate. Marketing Attribution Is a Myth 44:13There will never be a "cast iron steel rod of attribution" connecting marketing activities directly to purchases. Marketers who work for leadership that doesn't understand this are doomed to 18-month tenures, chasing MQL targets that deliver short-term sugar rushes followed by revenue crashes. The rare CEO or investor who recognizes this broken motion is the problem—not the marketer—creates space for real growth. Quote of the Show (44:13):"There will never be a cast iron steel rod of attribution that says marketing did X, which led to this person buying something. It just doesn't work that way.” — Ed Locher Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Ed Locher: LinkedIn: https://www.linkedin.com/in/edlocher/ Company Website: https://purefacts.com How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Siddharth Ugrankar, CEO & Co-Founder, Qila.ioBlockchain has long been associated with hype and experimentation, but its real value is now emerging in highly regulated environments like banking, insurance, and financial services. As institutions prioritise security, compliance, and transparency, enterprise-grade blockchain is becoming a practical foundation for next-generation financial infrastructure.  In this episode, Vriti Gothi speaks with Siddharth Ugrankar, CEO and Co-Founder of Qila.io, to unpack how blockchain can strengthen trust in banking systems, the role of private blockchains in CBDCs and cross-border settlements, and how tokenisation and smart contracts are reshaping financial markets. They also discuss India's evolving regulatory stance on data localisation and explore real-world use cases where blockchain is already delivering measurable impact across BFSI.

Green Isn't Easy|The Truth Behind ‘Sustainable' Transportation w/Kenneth ChesterToday's guest is Ken Chester, a nationally syndicated automotive journalist, tech communicator, and CEO of TechMobility Productions. With a media career spanning over three decades, Ken has been a leading voice at the intersection of mobility, technology, AI, personal privacy, and climate impact. From founding one of the first consumer-focused auto services in 1989 to producing nationally syndicated radio and podcast content, Ken brings unmatched insight into the evolving transportation landscape. He's also a founding member of the Black Automotive Media Group, championing diversity and representation in the industry. Get ready for a dynamic conversation that connects innovation with real-world impact.Links:https://thetechmobilitypodcast.buzzsprout.com/https://www.instagram.com/thetechmobilityshowTags:Adaptive Technology,,Artificial Intelligence (AI)Automation,Automotive,,Climate & SustainabilityElectric Vehicles,Mobility,Regulatory Compliance,Renewable Energy,Robotics,Live Video Podcast Interview,Podcast,Phantom Electric Ghost PodcastSupport PEG by checking out our Sponsors:Download and use Newsly for free now from www.newsly.me or from the link in the description, and use promo code “GHOST” and receive a 1-month free premium subscription.The best tool for getting podcast guests:https://podmatch.com/signup/phantomelectricghostSubscribe to our Instagram for exclusive content:https://www.instagram.com/expansive_sound_experiments/Subscribe to our YouTube https://youtube.com/@phantomelectricghost?si=rEyT56WQvDsAoRprRSShttps://anchor.fm/s/3b31908/podcast/rssSubstackhttps://substack.com/@phantomelectricghost?utm_source=edit-profile-page

Interested in a career at the Metropolitan Washington Airports Authority? See what we have available here: https://www.mwaa.com/careersHave questions for us? We'd love to hear from you! Send us an email at info@thecapitalrunway.comFor more information, please visit our website at https://thecapitalrunway.com.Staff:Tanisha Lewis, VP of Regulatory Compliance and Community EngagementJaimini Erskine, VP of Marketing & ConcessionsCharles Wilson, Co-host/Co-producerAmanda Ohbayashi, Co-host/Co-producer/Social media producerBong Lee, GraphicsBrian McCoy, Digital Strategy/Co-producerSagia Depty, Marketing Lead/Co-producer

Interested in a career at the Metropolitan Washington Airports Authority? See what we have available here: https://www.mwaa.com/careersHave questions for us? We'd love to hear from you! Send us an email at info@thecapitalrunway.comFor more information, please visit our website at https://thecapitalrunway.com.Staff:Tanisha Lewis, VP of Regulatory Compliance and Community EngagementJaimini Erskine, VP of Marketing & ConcessionsCharles Wilson, Co-host/Co-producerAmanda Ohbayashi, Co-host/Co-producer/Social media producerBong Lee, GraphicsBrian McCoy, Digital Strategy/Co-producerSagia Depty, Marketing Lead/Co-producer

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant updates that are shaping the future of healthcare, patient care, and drug development.The U.S. Food and Drug Administration has been particularly active recently, granting Johnson & Johnson a National Priority Review Voucher for its multiple myeloma drug combination. This move highlights the importance of J&J's treatment in addressing unmet needs within oncology, a field continuously striving for innovative solutions. These vouchers expedite the review process, reflecting a broader commitment to accelerating the availability of critical therapies for patients who need them most.Continuing with regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu, in combination with Roche's Perjeta, has gained FDA approval as a first-line treatment for unresectable or metastatic HER2-positive breast cancer. This breakthrough is supported by late-stage study results demonstrating a 44% reduction in disease progression or death compared to standard care. The approval signifies not only progress in breast cancer therapeutics but also underscores the potential benefits of strategic collaborations in drug development. Such partnerships are increasingly vital as they aim to optimize therapeutic efficacy through shared expertise and resources.In contrast to these advancements, Pfizer is facing financial recalibrations with projected revenues for 2026 estimated to decline due to diminishing COVID-19 vaccine sales and patent expirations. This situation reflects broader industry challenges as companies navigate post-pandemic market dynamics and patent cliffs, forcing reevaluations of long-term strategies.On another front, Gilead Sciences continues to push boundaries in HIV treatment with a promising single-tablet regimen combining bictegravir and lenacapavir. This innovation targets underserved segments within the HIV market, offering streamlined treatment options that could enhance patient adherence and outcomes significantly.Shifting focus to obesity management, Novo Nordisk's oral semaglutide is emerging as a highly anticipated medication among primary care providers. This trend highlights a growing preference for oral GLP-1 therapies as convenient alternatives to injectable formulations, marking a shift in how obesity—a major public health concern—is managed.The importance of regulatory compliance remains evident as Novo Nordisk received an FDA warning letter concerning manufacturing issues at an Indiana site previously owned by Catalent. This incident underscores the necessity for rigorous quality control in pharmaceutical manufacturing, which can have far-reaching implications on operational dynamics and supply chains.The FDA is also pioneering efforts to incorporate real-world evidence into medical device submissions by opening pathways for extensive deidentified datasets from sources like national cancer registries and electronic health records. This policy shift aims to integrate diverse data sources into the evidentiary foundation for medical device evaluations, potentially fostering innovation within this sector.In line with collaborative efforts, Genentech has partnered with Caris Life Sciences in a multi-year agreement valued at up to $1.1 billion, emphasizing the strategic importance of integrating diagnostic advancements with therapeutic developments to achieve precision medicine goals.Meanwhile, Yarrow Bioscience has acquired an autoimmune thyroid disease drug from China's Gensci, exemplifying a growing trend of cross-border collaborations aimed at leveraging global innovation ecosystems to address diverse therapeutic areas. This acquisition is part of a $1.37 billion deal, reinforcing the globalization of biotech partnerships as companies seek access to novel therapeutics andSupport the show

In "Trimble's Perspective: The Future of Freight is Connected", Joe Lynch and Rob Painter, Trimble's President and Chief Executive Officer, discuss how Trimble connects the freight ecosystem—people, data, and workflows—to navigate the difficult truckload market and drive customer efficiency using AI and integrated commercial solutions. About Rob Painter Rob Painter became Trimble's president and chief executive officer in January 2020. From 2016 through 2019, he served as the Company's chief financial officer. Joining the Company in 2006, Painter held a variety of leadership positions, including corporate development, corporate strategy, general manager of Construction Services, general manager of the Intelligent Construction Tools international joint venture, and vice president of Trimble Buildings construction software. In August 2023, he was appointed to serve on the Synopsys Board of Directors. Painter holds a bachelor's degree in finance from West Virginia University and an MBA from Harvard University. About Trimble Transportation Trimble Transportation provides fleets with solutions to create a fully integrated supply chain. With an intelligent ecosystem of products and services, Trimble Transportation enables customers to embrace the rapid technological evolution of the industry and connect all aspects of transportation and logistics — trucks, drivers, back office, freight and assets. Trimble Transportation delivers an open, scalable platform to help customers make more informed decisions and maximize performance, visibility and safety. Key Takeaways: Trimble's Perspective: The Future of Freight is Connected In "Trimble's Perspective: The Future of Freight is Connected", Joe Lynch and Rob Painter, Trimble's President and Chief Executive Officer, discuss how Trimble connects the freight ecosystem—people, data, and workflows—to navigate the difficult truckload market and drive customer efficiency using AI and integrated commercial solutions. Holistic Solution for a Difficult Truckload Market: Trimble's T&L segment directly addresses the pressures of the current truckload market by providing core operational platforms (TMW.Suite, TruckMate) to help carriers, shippers, and brokers manage operations, accounting, and dispatch, ensuring maximum efficiency and cost control when margins are tight. Driving Strategy with the Connect & Scale Message: The entire product portfolio—spanning TMS, maintenance, visibility, and procurement—is structured to embody Trimble's "Connect & Scale" message, which focuses on integrating people, data, and workflows into a unified ecosystem to drive growth and efficiency. AI-Powered Autonomous Freight Procurement: Trimble is leveraging AI within its Freight Procurement solutions (Transporeon, Freight Marketplace) to move toward autonomous procurement. This helps shippers and brokers efficiently source capacity and optimize freight spend in real-time, which is critical in a volatile capacity environment. Commercial Mapping for Efficiency and Safety: Essential tools like Trimble MAPS (CoPilot, Appian) go beyond basic navigation. They provide commercial-grade routing that accounts for truck-specific constraints and HOS, acting as a crucial element in optimizing routes and protecting drivers (part of the people and workflow components of Connect & Scale). TMS as the Core Workflow Integrator: Comprehensive Transportation Management Systems (TMS) platforms like TMW.Suite act as the central brain for workflows, integrating data across the business from operations to financial accounting, which is foundational to the "Scale" component of Trimble's strategy. Proactive Maintenance and Data Connectivity: Solutions for Asset & Fleet Maintenance focus on maximizing uptime—a key lever in today's market. By using data from connected trucks (fault codes, location) for preventative and predictive maintenance, they ensure assets remain productive and reduce unexpected downtime. Regulatory Compliance and Risk Mitigation (People & Data): The Safety & Compliance offerings help fleets mitigate risk and adhere to federal regulations, ensuring the safety and legal operation of their people (drivers) and assets, proving that technology is essential for responsible management and effective use of operational data. Learn More About Trimble's Perspective: The Future of Freight is Connected Rob Painter | Linkedin Trimble Transportation | Linkedin Trimble Transportation Revolutionizing the Road: Trimble's Tech Solutions with Kelly Williams | The Logistics of Logistics Trimble & Platform Science: The Future of Telematics with Rob Painter and Jack Kennedy The Logistics of Logistics Podcast If you enjoy the podcast, please leave a positive review, subscribe, and share it with your friends and colleagues. The Logistics of Logistics Podcast: Google, Apple, Castbox, Spotify, Stitcher, PlayerFM, Tunein, Podbean, Owltail, Libsyn, Overcast Check out The Logistics of Logistics on Youtube

Security used to be a headache. Now it is a growth engine.In this episode of IT Visionaries, host Chris Brandt sits down with Taylor Hersom, Founder and CEO of Eden Data and former CISO, to break down how fast growing companies can turn cybersecurity and compliance into a true competitive advantage. Taylor explains why frameworks like SOC 2, ISO 27001, and emerging AI standards such as ISO 42001 are becoming essential for winning enterprise business. He also shares how to future proof controls, connect compliance work to real business goals, and avoid the costly pitfalls that stall companies during scale.Taylor also highlights the biggest blind spots in AI security, including model training risks, improper data handling, and the challenges created by relying on free AI tools. If you are building a SaaS product or selling into large companies, this conversation shows how trust, transparency, and strong security practices directly drive revenue. Key Moments:  00:00 — The Hidden Risks of Scattered Company Data04:11 — Why Early-Stage Teams Lose Control of Security08:22 — Compliance Becomes a Competitive Advantage12:33 — SOC 2 vs ISO 27001: What Founders Need to Know16:44 — Framework Overload and How to Navigate It20:55 — Mapping Security Controls to Business Objectives25:06 — The Gap Between Compliance Audits and Real Threats29:17 — Startup Security Blind Spots That Lead to Breaches33:28 — Rising AI Risks Leaders Aren't Preparing For37:39 — Building Customer Trust Through Transparency41:50 — Protecting AI Models and Sensitive Customer Data46:01 — Why Free AI Tools Create Hidden Data Exposure50:12 — Automating Security Controls for Scale54:23 — Continuous Compliance Beats Annual Audits58:34 — Final Takeaways on Security, Trust, and Growth -- This episode of IT Visionaries is brought to you by Meter - the company building better networks. Businesses today are frustrated with outdated providers, rigid pricing, and fragmented tools. Meter changes that with a single integrated solution that covers everything wired, wireless, and even cellular networking. They design the hardware, write the firmware, build the software, and manage it all so your team doesn't have to.That means you get fast, secure, and scalable connectivity without the complexity of juggling multiple providers. Thanks to meter for sponsoring. Go to meter.com/itv to book a demo.---IT Visionaries is made by the team at Mission.org. Learn more about our media studio and network of podcasts at mission.org. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Anne Marie Engel is a third-generation attorney and a fierce advocate for restoring integrity to the legal profession. With deep expertise in employment law, contracts, and regulatory compliance, she helps medium to large businesses, in healthcare, corporate, and government sectors navigate today's complex legal landscape without compromising their values. Anne Marie is the creator of the “Accountability Architecture” framework, which empowers organizations to ensure their legal teams act with true fiduciary loyalty and operational impact. A bold voice against the complacency of Big Law and politicized legal trends, she challenges the status quo by centering constitutional principles, ethical leadership, and legal clarity. She currently practices at Crown Legal and her project, Flourish Professional Development which focuses on women lawyers and leadership Whether she's leading executive workshops or advising ethics-driven CEOs, Anne Marie brings a rare blend of legal rigor and moral courage to every conversation. For more information, visit www.linkedin.com/in/anengel.

Christine Lowthian, Head of Regulatory Compliance at HSBC, on her career journey, the importance of seizing opportunities and building a supportive network. She highlights her experience leading global teams, particularly in commercial banking and the U.S., and the challenges of managing multicultural teams. Lowthian stresses the role of technology, particularly AI, in enhancing compliance efficiency but noted the need for clean data. She advises aspiring leaders to embrace opportunities, maintain open communication with boards and regulators, and focus on strategic thinking and continuous improvement. SHOW NOTES 02:12 Career Journey 05:46 Leading Global Teams 08:50 Managing Multicultural Teams 16:27 Skills for the Compliance Officer of the Future 17:57 Engaging with Boards and Regulators 26:29 Handling Challenging Personalities 29:05 Advice for Women Starting Out Transcript and more GRC content: https://www.riskywomen.org/2025/11/podcast-s813-leading-global-teams-managing-with-impact-christine-lowthian/

Interested in a career at the Metropolitan Washington Airports Authority? See what we have available here: https://www.mwaa.com/careersHave questions for us? We'd love to hear from you! Send us an email at info@thecapitalrunway.comFor more information, please visit our website at https://thecapitalrunway.com.Staff:Tanisha Lewis, VP of Regulatory Compliance and Community EngagementJaimini Erskine, VP of Marketing & ConcessionsCharles Wilson, Co-host/Co-producerAmanda Ohbayashi, Co-host/Co-producer/Social media producerBong Lee, GraphicsBrian McCoy, Digital Strategy/Co-producerSagia Depty, Marketing Lead/Co-producer

Want a legal career blending Intellectual Property (IP), Biotechnology, and Business? We sit down with Jenna Matheny (Vice-President & Managing Director at APIOiX) to break down the path to a high-impact career in medical innovation. This episode is essential listening for law students and those interested in patent law who also have a passion for science, revealing a world of opportunities beyond traditional law firm life.In this episode, we discuss:The Innovation Lifecycle: How lawyers are involved from invention disclosure and patent strategy to regulatory approval (FDA) and commercialization.The Business of IP: The critical, often-overlooked importance of contracting and compliance in developing and licensing medical technology.Finding Your Niche: Jenna's unique career path through university Tech Transfer offices, incubators, and accelerators—and how law students can get their foot in the door.Beyond Science: The growing field of social innovation and how non-science majors can find rewarding IP careers focused on copyright and trademark.Practical Law School Advice: Which broad-based courses (like securities and international tax) set you up for success, and the value of clinics and residencies.(00:00) - Introduction: Blending Law, Science, and Business in an IP Career (01:43) - Meet Jenna Matheny: Expert in Medical Technology IP and Tech Consulting (04:28) - Defining Biotech vs. MedTech: Law's Role in FDA Approval (05:42) - The Core Practice Areas: Patents, Contracting, and Regulatory Compliance (10:09) - Career Pivot: From Medicine Interest to Patent Attorney Path (11:32) - Tech Transfer Offices (TTOs): How Law Students Can Gain Experience (14:28) - Incubators & Accelerators: Consulting and Internship Roles for Attorneys (20:39) - Practical Advice: Essential Law School Courses (Securities, Tax) and Clinics (24:26) - Serendipity & Networking: How Connections Change the Course of a Legal Career (25:59) - Social Innovation: IP Opportunities without a Science Background (Copyright & Trademark) Click here to view the episode transcript.

In this episode, the hosts delve into a shocking insider trading scandal involving the NBA, where organized crime intersects with professional basketball. They discuss the details of the schemes, the players involved, and the motivations behind such risky behavior. The conversation highlights the implications of integrity in sports and the legal challenges faced by those implicated in the fraud. In this conversation, Mark and Matthew delve into the intricate world of insider trading, gambling schemes, and the implications of cheating in professional sports. They explore the mechanics of poker cheating, the role of the mafia in enforcing debts, and the challenges of preventing fraud in gambling. The discussion also touches on regulatory measures and the integrity of professional sports, particularly in the context of the NBA and its investigations.Find us on all streaming platforms! Check out our sponsor 1Trooper on LinkedIn @1Trooper And don't forget to subscribe!

nterested in a career at the Metropolitan Washington Airports Authority? See what we have available here: https://www.mwaa.com/careersHave questions for us? We'd love to hear from you! Send us an email at info@thecapitalrunway.comFor more information, please visit our website at https://thecapitalrunway.com.Staff:Tanisha Lewis, VP of Regulatory Compliance and Community EngagementJaimini Erskine, VP of Marketing & ConcessionsCharles Wilson, Co-host/Co-producerAmanda Ohbayashi, Co-host/Co-producer/Social media producerRyan Burdick, Editor/Co-producerBong Lee, GraphicsBrian McCoy, Digital Strategy/Co-producerSagia Depty, Marketing Lead/Co-producer

US Government Shutdown – What the FDA Can Still Be Doing? When the U.S. government experiences a shutdown, the consequences ripple across every industry — but for medical device manufacturers, the uncertainty can be alarming. In this article, Regulatory Expert Rob Packard explores what happens to the U.S. Food and Drug Administration (FDA) during a shutdown, and how it affects global manufacturers. You'll learn: Which FDA activities continue, and which are suspended How submissions like 510(k), PMA, and De Novo are impacted What happens to clinical trials, recalls, and ongoing investigations Whether this situation has happened before and how long it could last How companies can prepare and what contingency actions to take

ENR Editors Aileen Cho and Pam McFarland talk with the former chief counsel to the FHWA and now principal advisor to Jacobs about the goal of achieving more streamlined review processes while still being environmentally responsible. Sponsored by: CMiC

What if AI ran your bank?

In this conversation, Aidan Larkin sits down with Dr. Max Bernt (TaxBit) to explore the future of asset recovery in a digital-first world. They dive into how data aggregation, crypto, and stablecoins are transforming investigations - and why practitioners have reason for optimism. Timestamps00:00 – Introduction and Background 04:00 – Inside the Digital Asset Recovery Ecosystem 09:48 – How TaxBit Bridges On-Chain and Off-Chain Data 16:00 – Real-World Cases & Lessons Learned 27:50 – Tackling Data Challenges & Regulatory Hurdles 32:09 – Stablecoins: Risks and Opportunities 40:49 – The Future of Financial Crime Investigations 51:03 – Why There's Reason for Optimism in Recovery About our Guest Dr. Max Bernt is TaxBit's Global Head of Regulatory Affairs and Managing Director for Europe. With a robust background in transnational criminal law and extensive experience in regulatory affairs, he advises on cases and policy involving cryptocurrency, financial crime, and digital asset recovery. Max has helped shape discussions around the intersection of law enforcement and crypto, exploring how data aggregation, stablecoins, and regulatory frameworks impact investigations and compliance. Key Takeaways Evolving Asset Recovery Ecosystem: Technology is driving the evolution of the asset recovery ecosystem, creating new tools and approaches for practitioners. Importance of Data Aggregation: Effective investigations rely on robust data aggregation, helping practitioners identify patterns and trace assets efficiently. Bridging On-Chain and Off-Chain Data: TaxBit serves as a critical bridge between on- and off-chain data, enabling more accurate and comprehensive investigations. Impact of Regulatory Changes: Shifting regulations will have a significant effect on financial crime investigations, requiring practitioners to adapt strategies accordingly. Opportunities and Challenges of Stablecoins: Stablecoins present both opportunities and challenges for investigators, influencing how digital assets are tracked and recovered. Optimism for the Future of Asset Recovery: Despite the challenges, practitioners can be optimistic about future advancements, including improved efficiency, technology, and collaboration in the field. Resources Mentioned Taxbit Stay Connected Dive deeper into the world of asset recovery by subscribing to Seize & Desist: https://link.cohostpodcasting.com/b36b929c-6ca3-4e49-8258-44c310d012c9?d=sG5Qi2MdL DisclaimerOur podcasts are for informational purposes only. They are not intended to provide legal, tax, financial, and/or investment advice. Listeners must consult their own advisors before making decisions on the topics discussed. Asset Reality has no responsibility or liability for any decision made or any other acts or omissions in connection with your use of this material. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Asset Reality employees are those of the employees and do not necessarily reflect the views of the company. Asset Reality does not guarantee or warrant the accuracy, completeness, timeliness, suitability or validity of the information in any particular podcast and will not be responsible for any claim attributable to errors, omissions, or other inaccuracies of any part of such material. Unless stated otherwise, reference to any specific product or entity does not constitute an endorsement or recommendation by Asset Reality.

In this episode, host Etienne Nichols sits down with Jose Bohorquez and Mohamad Foustok from CyberMed to dissect the complex world of Software as a Medical Device (SaMD) and cybersecurity. They emphasize that SaMD is first and foremost a medical device and should be treated as such from the very beginning of the development process. The conversation highlights the most common mistakes companies make, like treating security as an afterthought and jumping straight into coding without a solid architectural plan.Mohamad Foustok introduces the concept of "zero trust" and the critical importance of designing for security across the entire product lifecycle, from initial concept to post-market surveillance. The discussion clarifies that cybersecurity is not limited to network-connected devices but applies to any medical device with a software function, regardless of its connectivity. They also touch on the historical context of FDA guidance, noting a significant shift in recent years that has raised the regulatory bar and put a greater emphasis on robust cybersecurity documentation.The guests provide actionable advice for MedTech professionals, stressing the value of a balanced approach that integrates security and functionality from day one. They explain that a well-thought-out process, though seemingly slower at the outset, ultimately saves time and resources by preventing costly and time-consuming redesigns later on. This episode serves as a vital guide for anyone looking to build a secure and compliant medical device in today's evolving regulatory landscape.Key Timestamps[01:50] Common pitfalls in developing SaMD, including overlooking regulatory guidance like IEC 62304.[03:20] The critical mistake of treating cybersecurity as an afterthought in product development.[05:00] Who cybersecurity applies to beyond software, including patients, manufacturers, and supply chains.[06:30] The FDA's stance on cybersecurity for any device with a software function, even if not network-connected.[08:00] A discussion on "reasonable assurance of cybersecurity" and what it means for manufacturers.[10:00] The "zero trust" principle and why you should never assume a network is secure.[14:00] How hospitals and other stakeholders are demanding more rigorous cybersecurity standards.[15:40] The ideal process for a "security-first" development lifecycle.[21:00] Why rushing development without a proper architecture can lead to significant delays and cost overruns.[23:00] A brief history of FDA's cybersecurity guidance and the major shift in 2023.Quotes"Software as a medical device ultimately is a medical device, and so you want to be developing it from the get-go with that mindset." — Jose Bohorquez"Security can't be an afterthought. You have to consider security at the inception of your approach to a product." — Mohamed FustokTakeawaysA "Security-First" Mindset is Essential: Integrate cybersecurity from the initial architectural phase of your project. This proactive approach saves significant time and money by avoiding costly redesigns and delays later in the development process or after an FDA submission.Cybersecurity is for All Software-Driven Devices: Don't assume that only cloud-connected devices need cybersecurity documentation. The FDA requires documentation for any device with a software function, including embedded systems and programmable logic, even if it's not connected to a network.Regulatory Compliance is a Process, Not a...

In this episode of Disruption/Interruption, host KJ interviews Dr. Paola Ballester, CEO and Co-founder of EasyPA, about the broken state of prior authorizations in healthcare. Dr. Ballester shares her journey from pediatrician to tech founder, the real-world impact of administrative burdens on patients and clinicians, and how her AI-driven platform is streamlining processes to put patient care back at the center. Key Takeaways: The Real Cost of Prior Authorizations [2:05] – Administrative hurdles in healthcare lead to denied claims, lost revenue, and wasted time, forcing clinicians to choose between paperwork and patient care. Empathy Drives Disruption [4:35] – Dr. Ballester’s deep empathy for patients and providers inspired her to create a solution that addresses the root frustrations in the system. AI as a Force for Good [27:05] – EasyPA’s AI platform modernizes prior authorizations, making them 10x faster and giving clinicians more time with patients, not paperwork. Systemic Change is Possible [36:45] – With new technology, regulatory mandates, and a focus on patient-centered care, the healthcare system can move beyond outdated, inefficient processes. Quote of the Show [19:40]:"The assumption that physicians need to prove on a per case basis that their intent is anything other than to provide direct patient care based on evidence-based standards is wild." - Paola Ballester Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Dr. Paola Ballester: LinkedIn: https://www.linkedin.com/in/paola-ballester-md-7738a9a8/ Company websites: easypa.ai How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Solidus Labs launches The FoRC: The Future of Regulatory Compliance with Dante Disparte of Circle. They explore how stablecoins are driving financial inclusion, changing the compliance playbook, and redefining global finance. Topics include the GENIUS Act, blockchain-based monitoring, and Circle's newly announced Layer 1, Arc.

In this episode of RCA Radio, host Brandon Miller is joined by cybersecurity experts Jason Tugman of Regulatory Compliance Associates® and Mustanger Ali of BSI to unpack the evolving landscape of cybersecurity in medical devices. Together, they explore the latest FDA and EU guidance, the growing expectations for connected device security, and the top gaps companies face when bringing products to market. From threat modeling and SBOMs to legacy device challenges and global regulatory alignment, this episode offers practical insights for MedTech developers navigating today's complex cybersecurity requirements. Whether you're launching a new device or updating an existing one, this conversation is packed with actionable advice to help you stay secure and compliant. 

Welcome to the American Railroading Podcast! In this episode our host Don Walsh is joined by guest Tom DeLafosse, SVP of Quality and Regulatory Compliance for Salco Products. Together they do a deep dive into tank car regulations, rulings and pending rulings such as HM-216b, HM-265 and HM-264, including the history of the industry before these regulations and rulings, the reasoning behind the creation of them, and their current as well as potential future impact on car owners, repair shops and shippers. They also take a brief moment to discuss the history of Salco Products and A. Stucki. Tune in to this episode to gain valuable insights and broaden your understanding of American Railroading! You can find this episode and more on the American Railroading Podcast's official website at www.AmericanRailroading.net , and watch our YouTube Channel at the link below. Welcome aboard!KEY POINTS: The American Railroading Podcast remains in the Top 10% of all podcasts globally, now downloaded in 53 countries around the world!The podcast has experienced incredible growth in the last month, including a 300% increase in audio and video downloads!Tom has 50 years of experience in the railcar industry in quality assurance, design, repair and inspection of railroad tank cars.Don trained under Tom for his Level II NDT certifications in 1998, shortly after he entered the industry.Today there are approximately 2 million registered railcars in the U.S. national fleet, of which 22% (or 440,000) are tank cars, all of which require HM-216b qualification at regular intervals.Tom and Don discuss the challenges tank car certified repair shops face today, and some of the potential causes for lengthy shop cycle times.Tom gives his very detailed thoughts on the pending ruling HM-265, as well as his opinion of the potential pros and cons.Don provides a final update from PHMSA on HM-264.Please submit your favorite veteran of our U.S. Armed Forces currently in or retired from the rail industry for our 3rd Annual – American Railroading Podcast - Honor our Heroes Award, sponsored by our friends at Boots for Troops in Tomball, TX. by 09/12/25. Details given in the episode.If you like what we do, please leave us a 5-Star Review!LINKS MENTIONED: https://www.americanrailroading.nethttps://www.therevolutionrailgroup.com https://www.youtube.com/@americanrailroadingpodcast https://www.buymeacoffee.com/dwalshX https://www.enviroserve.com https://www.salcoproducts.comhttps://www.stucki.com

This week on the Oakley Podcast, host Jeremy Kellett chats with Myers Buck & Jack Pinkerton, some of our dispatchers at Oakley Trucking. Myers and Jack share their journeys from shop work to dispatching, discussing the day-to-day challenges of managing drivers and loads, as well as the importance of communication, flexibility, and teamwork in the trucking industry. Listeners will gain insights into the human side of dispatching, the value of building strong relationships with drivers, and the critical role dispatchers play in ensuring both company and driver success. Key takeaways include the need for adaptability, clear communication, and understanding the unique challenges faced by both dispatchers and drivers. Don't miss this inside look at how dispatchers keep trucks on the road. Key topics in today's conversation include:Meet Myers and Jack: Backgrounds and How They Joined Oakley (1:03)First Impressions and Shop Experience (2:55)Transition to Dispatch: Learning the Ropes (7:26)Challenges of Dispatching and Building Relationships (9:23)A Day in the Life of a Dispatcher (12:15)Ensuring Drivers' Earnings and Settlement Checks (14:21)Regulatory Compliance and Administrative Duties (17:02)Building Personal Relationships with Drivers (21:04)Orientation and Understanding Driver Rules (24:22)Load Planning and Communication with Drivers (26:15)Customer Interaction and Cold Calling for Freight (29:17)Advice for Drivers: Flexibility and Communication (33:15)Company Culture and Camaraderie (34:53)Final Thoughts and Takeaways (36:41)Oakley Trucking is a family-owned and operated trucking company headquartered in North Little Rock, Arkansas. For more information, check out our show website: podcast.bruceoakley.com.

In this episode of Cut the Mic, Mike Hoeflich and Mike Sperrazza dive into the importance of personal responsibility in today's culture and the consequences of relying too heavily on government support. The Mikes also break down the economic ripple effects of Trump's global trade deals, including a major win with the EU and Japan that's boosting U.S. markets. Plus, they sound the alarm on rising taxes in Buffalo and what it could mean for the region's future.(00:06:52) Emphasizing Personal Responsibility for Societal Well-being(00:09:05) Tariff Negotiations Yield Positive Economic Growth(00:09:05) Impact of EU-US Trade Deal Tariffs(00:09:55) Trump's Trade Deal Initiatives Boost Markets(00:28:08) Tax Rate Impact on Buffalo Suburbs(00:29:53) Regulatory Compliance and Investor Protection Through Securities

Support Cannabis Reform in Texas. Heather Fazio of the Texas Cannabis Policy Center.Heather is a dedicated cannabis advocate with a strong track record of advancing reform efforts in Texas. She discusses policy with Jay Maguire of the Texas Hemp Federation and CRAFT. Cannabis Regulatory Alignment Framework & Training Jasmine Brennan serves clients in Strategy, Regulatory Compliance, Startups, Cannabis & Hemp, & Alternative Beverages. Jasmine Website is https://www.mindfulcompliance.com/ Heather Website is https://texascannabispolicy.org/ Russell Dowden websites are: https://blazednews.com/ & https://texashempreporter.com/ Jay Maguire website is https://www.joincraft.org/Rachel Nelson website is http://thenotorious.tv/

Human Resources and Workforce Impact: Bias in Automation: Ensure that automated HR processes undergo regular audits to identify and mitigate biases, particularly in candidate selection and hiring. Regulatory Oversight: Implement annual bias audits for automated employment decision tools to comply with regulations. Employee Surveillance: Review and update employee monitoring practices to ensure compliance with privacy regulations, and OSHA and HIPAA. Regulatory Compliance and Legal Risks: Decentralized AI Regulation: Develop a comprehensive strategy to track and comply with AI regulations across different states. EU AI Act: Assess the impact of the EU AI Act on your operations and ensure compliance with its requirements, even if your systems are used within the EU. Terms of Service: Establish a process to monitor and review changes in terms of service for AI, other technology and communications tools, ensuring compliance and proper data usage. Operational Resilience and Business Continuity: System Dependencies: Regularly evaluate AI systems for data representativeness and bias and adapt to real-time changes in company operations. Supply Chain Vulnerabilities: Conduct frequent audits of third-party components and vendors to identify and mitigate supply chain vulnerabilities. Cyber Threats: Update employee training programs to include awareness and prevention of deepfake scams and other sophisticated cyber threats. Strategic Oversight and Accountability: Ethical Considerations: Form multidisciplinary task forces for AI adoption, including general counsel, to classify use cases based on risk levels. ROI and Uncertainty: Ask for detailed ROI estimates, timelines, and milestones for AI projects, considering the uncertainty and potential qualitative outcomes. Director Education: Encourage directors to engage in educational opportunities, such as NACD masterclasses and other governance-focused content, to enhance their understanding of AI governance.

Luke Marsden, CEO and Founder, HelixML talks about Private GenAI. What is it? Why do you need it? We also discuss integration into CI/CD pipelines, the layers of a Private GenAI Stack, and why most organizations are opting for RAG over fine-tuning LLMs.SHOW: 943SHOW TRANSCRIPT: The Cloudcast #943 TranscriptSHOW VIDEO: https://youtube.com/@TheCloudcastNET NEW TO CLOUD? CHECK OUT OUR OTHER PODCAST:  "CLOUDCAST BASICS" SPONSORS:[DoIT] Visit doit.com (that's d-o-i-t.com) to unlock intent-aware FinOps at scale with DoiT Cloud Intelligence.[FCTR] Try FCTR.io (that's F-C-T-R dot io) free for 60 days. Modern security demands modern solutions. Check out Fctr's Tako AI, the first AI agent for Okta, on their website[VASION] Vasion Print eliminates the need for print servers by enabling secure, cloud-based printing from any device, anywhere. Get a custom demo to see the difference for yourself.SHOW NOTES:HelixML websiteHelixML GitHubHelix 1.0 Announcement BlogTopic 1 - Welcome to the show Luke. Give everyone a brief intro.Topic 2 - Let's start with Priavte GenAI. What is it? Why should organizations out there consider it? Why not just use OpenAI GPT's and fine tune them?Topic 2a Follow up - Regulatory Compliance - take the opposing forces in the EU for instance to using SaaS based services based in the United States.Topic 3 - Let's break down the layers in a typical Private AI stack. I'm seen various ways to represent this such as infrastructure layer, MLOps layer, models, data layer (typically RAG), etc. How do you break up the stack into individual componentsTopic 4 - My mind immediately jumps to similarities in the DevOps space. Abstraction layers and components like Docker and containers comes to mind, integration into CI/CD pipelines, etc. I feel like MLOps is it's own thing with specific tools and workflows. Does this all come together and if so how?Topic 5 - Also, what does this mean for versioning and lifecycle management of the models and the data?Topic 6 - We are seeing more and more data pipelines with backed by multiple models, sometimes in multiple locations. How do handle this from both a scheduling and interface standpoint? Is everything hidden behind APIs for instance?Topic 7 - If anyone is interested, what's the best way to get started?FEEDBACK?Email: show at the cloudcast dot netBluesky: @cloudcastpod.bsky.socialTwitter/X: @cloudcastpodInstagram: @cloudcastpodTikTok: @cloudcastpod

  Background: From IT in India to MedTech in Norway  You have a pretty fascinating background – you studied computer applications/IT back in India and now you're a Quality/Regulatory Manager in the Norwegian medtech scene. Can you walk us through that journey? How did you go from an IT degree in India to working with medical device regulations in Norway? (What prompted the move and career change?)  What were the biggest challenges when you switched into the medical devices field? For example, was there a steep learning curve with all the medical and regulatory jargon?  And conversely, do you think your IT background gives you any unique advantages in QARA? (Maybe in handling technical documentation or bringing a fresh perspective?)  Day-to-Day as a QARA Manager   Let's talk about what a QARA Manager actually does. What does a typical day or week look like for you as a Quality and Regulatory Affairs Manager? (For instance, are you reviewing a lot of documents, meeting with engineers, training colleagues, dealing with audits… all of the above?)  It would be great if you could mention some of the tools or software you use regularly. Are there specific QMS (Quality Management System) tools, document control systems, or even simple spreadsheets that are part of your daily routine?  We often hear that QA/RA folks are like the “internal police” in a company – some colleagues think you just spend days reading boring regulations and chasing them to follow rules (laughs). How true or untrue is that stereotype? How would you describe the role to someone who thinks it might be dry or overly bureaucratic?  On that note, an article I read actually said quality and regulatory roles are among the most dynamic and diverse in a company. You have to know a bit of everything – the tech, the laws, writing skills, you name it. What parts of the QARA role do you find most challenging, and which parts are the most rewarding?  (For example, is it challenging that the scope is so broad – one moment you're deep in engineering specs, next moment you're updating a regulatory policy? And rewarding perhaps when a product finally gets approved or when you prevent a big issue?)  First MedTech Role at Hy5Pro AS  Let's dive into your work experiences. Your first QARA role in Norway was at Hy5Pro AS, a startup developing a pretty cool product – a hydraulic prosthetic hand for amputees. What was it like stepping into Quality/Regulatory at a company making robotic hands?  (Feel free to explain what Hy5Pro's product was and your role there, e.g. implementing the quality system, getting certifications, etc.)  Do you have any memorable anecdotes from Hy5Pro? Perhaps a big challenge you faced early on or a funny incident while working on the prosthetic hand project. For instance, a lot of startups at that stage are trying to get their first ISO 13485 certification or pass initial regulatory hurdles – any story around that?  (e.g. “the day the auditors came for ISO certification” or a time something went wrong and how the team fixed it – anything that was a learning moment for you.)  Leading QARA at RemovAid AS   After Hy5, you moved on to RemovAid AS, which is another fascinating company – they created a device for removing contraceptive implants (a small gadget to help doctors remove those under-the-skin birth control implants). And I believe you were Head of Quality Assurance & Regulatory Compliance there. What were your main responsibilities at RemovAid, and how did it differ from your previous role?  RemovAid's product is a Class IIa medical device and was CE-marked under the new EU Medical Device Regulation. That sounds like a huge regulatory achievement. Can you share a proud moment from your time at RemovAid? For example, leading the company to ISO 13485 quality certification, or getting that CE approval, or the first time the device was manufactured at scale.  (We saw on LinkedIn you celebrated the first RemovAid device coming off a high-volume production line – feel free to tell that story!)  On the flipside, any tough or funny moments while at RemovAid? Perhaps juggling multiple roles in a small startup, or an unexpected problem that popped up (like a quirky product test failure or a documentation marathon just before a deadline)?  RemovAid is in women's health tech. Did working on a product aimed at female healthcare bring any special perspective or motivation for you? (Given it's about making contraceptive care easier – that's quite impactful.)  Consulting Experience at LINK Medical   Now, currently you're working at LINK Medical as a Medical Device Manager in their Quality/Regulatory team. So you went from being in-house at startups to a consulting role where you support multiple companies. What has that transition been like? How is life as a consultant different from working within a single company?  I imagine as a consultant you get to see a variety of projects – different devices, different teams – which can be exciting. Can you share any interesting experiences from your consulting work so far? Maybe an example of a cool project you helped on, or a common mistake you see companies making with QARA that you help fix, or even a humorous experience of jumping into a new company's project mid-stream.  Also, how do you manage your time and sanity when juggling multiple clients or projects? That sounds challenging – any personal tricks you've learned for staying organized when everyone needs your expertise at once? (laughs – “the consultant life”)*  Diversity and International Career Insights   I'd like to touch on diversity and your international experience. You're a woman in the medtech industry and you've built your career across two countries and cultures. Have you faced any unique challenges as a woman working in medical devices and QARA? And what about being an international professional – any cultural adjustments or advantages you've noticed working in Norway compared to India?  The medtech industry, especially in leadership, still isn't very diverse – I read that less than a quarter of executive roles in medtech are held by women. How do you feel about the state of diversity in our field? Are things improving, and have you seen progress during your career?  What advice would you give to companies or teams to foster a more inclusive environment, especially in fields like quality and regulatory? (Since those teams often work with all departments, they can influence company culture too.)  Rapid-Fire Round   Host: Okay, Pardeep, to wrap up on a fun note, we have a rapid-fire round! I'll ask you a series of quick questions and you answer with the first thing that comes to mind. Ready? (brief pause) Go!  Question 1: What's one thing about your job that most people would be surprised to learn?  Question 2: What's the coolest medical device or gadget you've worked on or seen so far?  Question 3: Are you team coffee or tea? (What fuels your workdays?)  Question 4: Is there a quality/regulatory jargon or acronym you think is funny or confusing (and what does it actually mean)?  Question 5: If you weren't in QARA, what alternate career could you see yourself in?  Question 6: What's one Norwegian word or phrase you've picked up that you love to use? (Bonus: translate it for us!)*  Question 7: If your career journey were made into a movie title, what would it be? (Just for fun!)  (Guest gives rapid-fire answers with laughter and brief commentary.)  Advice and Closing   Now, before we sign off, I want to circle back to a more reflective note. What advice or words of inspiration do you have for junior professionals, students, or even folks thinking of switching careers into Quality and Regulatory in medtech? For someone listening who says, “This sounds interesting but also a bit overwhelming,” how can they prepare and what should they expect?  (For example, should they get familiar with certain regulations or take courses? Find a mentor? Be ready to continually learn? Share any practical tips.)  And maybe equally important, what should they not be scared of? People might think “Oh, I'm not a science or law expert, can I do this?” – any encouragement to help them overcome that hesitation?      Podcast Interview Questions for Pardeep Kaur (Reg compliance manager Oslo University Hospital)  Welcome & Setup  Can you briefly introduce yourself and describe your current role as a Quality & Regulatory Affairs Manager?  Career Journey  How did you go from earning a Computer Applications/IT degree in India to a QARA career in Norway?  What motivated you to switch into medical device regulations, and what were the biggest initial challenges?  In what ways has your IT background helped you excel in QARA?  Day-to-Day Responsibilities  What does a typical day or week look like for you as a QARA Manager?  Which tools or software (QMS systems, document controls, etc.) do you rely on most?  Is it true that QA/RA professionals are the “internal police”? How would you describe the role to someone who thinks it's all paperwork?  Which aspects of QARA do you find most challenging, and which are the most rewarding?  Hy5Pro AS Experience  What was it like implementing QARA at Hy5Pro, developing a hydraulic prosthetic hand?  Can you share a memorable “learning moment” or funny anecdote from your time there?  RemovAid AS Experience  At RemovAid, you led Quality & Regulatory for a Class IIa implant-removal device—what were your core responsibilities?  Describe a proud milestone (e.g., ISO 13485 certification or CE marking) and the story behind it.  Any unexpected or humorous challenges you overcame in that role?  How did working on a women's health product impact you personally?  LINK Medical Consulting  How has transitioning to a consulting role at LINK Medical differed from in-house QARA positions?  What's a standout project or recurring compliance issue you help clients solve?  How do you stay organized when juggling multiple clients and deadlines?  Diversity & International Insights  As a woman in medtech QARA, have you faced any unique challenges or opportunities?  What cultural adjustments did you experience moving from India to Norway?  How can medtech teams become more inclusive, especially in QA/RA?  Rapid-Fire Round  (Answer quickly with the first thing that comes to mind.)  One surprise fact about your job?  Coolest device or gadget you've worked on or seen?  Favorite (or funniest) QARA acronym—what does it mean?  Alternate career you might have chosen?  Norwegian word or phrase you love—translate it for us!  If your career were a movie title, what would it be?  Closing Advice  What practical steps should students or career-changers take to break into QARA?  What misconceptions shouldn't they be afraid of when considering this field?   

Send us a textWhen AI systems fail spectacularly, who pays the price? Part two of our conversation with global tech lawyer Gayle Gorvett tackles the million-dollar question every business leader is afraid to ask. With federal AI regulation potentially paused for a decade while technology races ahead at breakneck speed, companies are left creating their own rules in an accountability vacuum. Gayle reveals why waiting for government guidance could be a costly mistake and how smart businesses are turning governance policies into competitive advantages. From the EU AI Act's complexity challenges to state-by-state regulatory patchwork, this customer success playbook episode exposes the legal landmines hiding in your AI implementation—and shows you how to navigate them before they explode.Detailed AnalysisThe accountability crisis in AI represents one of the most pressing challenges facing modern businesses, yet most organizations remain dangerously unprepared. Gayle Gorvett's revelation about the federal government's proposed 10-year pause on state AI laws while crafting comprehensive regulation highlights a sobering reality: businesses must become their own regulatory bodies or risk operating in a legal minefield.The concept of "private regulation" that Gayle introduces becomes particularly relevant for customer success teams managing AI-powered interactions. When your chatbots handle customer complaints, your predictive models influence renewal decisions, or your recommendation engines shape customer experiences, the liability implications extend far beyond technical malfunctions. Every AI decision becomes a potential point of legal exposure, making governance frameworks essential risk management tools rather than optional compliance exercises.Perhaps most intriguingly, Gayle's perspective on governance policies as competitive differentiators challenges the common view of compliance as a business burden. In the customer success playbook framework, transparency becomes a trust-building mechanism that strengthens customer relationships rather than merely checking regulatory boxes. Companies that proactively communicate their AI governance practices position themselves as trustworthy partners in an industry where trust remains scarce.The legal profession's response to AI—requiring disclosure to clients and technical proficiency from practitioners—offers a compelling model for other industries. This approach acknowledges that AI literacy isn't just a technical requirement but a professional responsibility. For customer success leaders, this translates into a dual mandate: understanding AI capabilities enough to leverage them effectively while maintaining enough oversight to protect customer interests.The EU AI Act's implementation challenges that Gayle describes reveal the complexity of regulating rapidly evolving technology. Even comprehensive regulatory frameworks struggle to keep pace with innovation, reinforcing the importance of internal governance structures that can adapt quickly to new AI capabilities and emerging risks. This agility becomes particularly crucial for customer-facing teams who often serve as the first line of defense Kevin's offeringPlease Like, Comment, Share and Subscribe. You can also find the CS Playbook Podcast:YouTube - @CustomerSuccessPlaybookPodcastTwitter - @CS_PlaybookYou can find Kevin at:Metzgerbusiness.com - Kevin's person web siteKevin Metzger on Linked In.You can find Roman at:Roman Trebon on Linked In.

In this episode, Paul Galloway joins Pushpendra Mehta to explore compliance and network optimization in treasury. From KYC and BOI filings to payment screening, Paul shares leading practices for managing risk and ensuring uptime. Discover how strategic compliance and robust networks support security, resilience, and competitive advantage. Check out the Leading Practices in Treasury ebook or audiobook here: https://strategictreasurer.com/ebook-leading-practices-in-treasury/?utm_source=STEBKpage Prefer video? Watch the full version here: https://www.youtube.com/watch?v=XJotnXwxIvw